Product Pathways - Adhesion
SignalSilence® ILK1 siRNA I #6202
|Transfection||H (M) (R)|
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells, transfected with 50 nM non-targeted siRNA (-) or 100 nM SignalSilence® ILK1 siRNA I (+), using ILK1 Antibody #3862 and Cofilin Antibody #3312. The ILK1 antibody confirms silencing of ILK1 expression and the cofilin antibody controls for protein loading and specificity of ILK1 siRNA.
SignalSilence® ILK1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit ILK1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Directions for Use
CST recommends transfection with 100 nM ILK1 siRNA I 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Integrin-linked kinases (ILKs) couple integrins and growth factors to downstream pathways involved in cell survival, cell cycle control, cell-cell adhesion and cell motility (1). ILK functions as a scaffold bridging the extracellular matrix (ECM) and growth factor receptors to the actin cytoskeleton through interactions with integrin, PINCH (which links ILK to the RTKs via Nck2), CH-ILKBP and affixin (1). ILK phosphorylates Akt at Ser473, GSK-3 on Ser9, myosin light chain 2 (MLC2) on Ser18/Thr19, as well as affixin (2-5). These phosphorylation events are key regulatory steps in modulating the activities of the targets. ILK activity is stimulated by PI3 kinase and negatively regulated by the tumor suppressor PTEN and a PP2C protein phosphatase, ILKAP (1,3,6). It has been suggested that the conserved Ser343 residue in the activation loop plays a key role in the activation of ILK1 (2).
Small Interfering RNA (siRNA) has been used to specifically silence ILK expression in HEK-293 cells (7).
- Wu, C. and Dedhar, S. (2000) J. Biol. Chem. 155, 505-510.
- Persad, S. et al. (2001) J. Biol. Chem. 276, 27462-27469.
- Persad, S. et al. (2000) J. Cell Biol. 153, 1161-1173.
- Deng, J.T. et al. (2001) J. Biol. Chem. 276, 16365-16373.
- Yamaji, S. et al. (2001) J. Cell Biol. 153, 1251-1264.
- Morimoto, A.M. et al. (2000) Oncogene 19, 200-209.
- Troussard, A. A. et al. (2003) J. Biol. Chem. 278(25) , 22374-22378.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6528 SignalSilence® ILK1 siRNA II
- 3862 ILK1 Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.